Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corp develops orthobiologic products for spine fusion markets, with its work centered on bone regeneration using the recombinant human protein rhNELL-1. Its lead product candidate, NB1, combines rhNELL-1 with demineralized bone matrix and is tied to the company’s focus on targeted bone regeneration in spinal fusion, with rights also noted for trauma and osteoporosis applications.
News about BBLG commonly covers clinical-development progress, product-readiness milestones such as rhNELL-1 shelf-life validation, patent activity, financing transactions, Nasdaq listing compliance, and corporate updates on scientific and operational priorities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bone Biologics Corporation (NASDAQ: BBLG) has announced the approval of a multicenter pilot clinical trial for its NB1 bone graft by the Human Research Ethics Committee in Australia. The trial will enroll 30 adult patients undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease (DDD). This study aims to assess the safety and effectiveness of NB1, which showed promising results in animal studies. The company aims to capture a part of the $3 billion global market for spine fusion products. Furthermore, the long-term goal includes addressing osteoporosis and trauma, potentially tapping into additional markets valued at $11 billion and $8 billion, respectively.
Bone Biologics Corporation (NASDAQ: BBLG) has engaged Avania as the Contract Research Organization (CRO) for its upcoming pilot clinical trial of NB1, targeting degenerative disc disease patients undergoing Transforaminal Lumbar Interbody Fusion (TLIF). The multicenter trial will assess the safety and effectiveness of the NB1 bone graft in 30 subjects, anticipated to start in late 2023, pending ethics committee approval from the Monash Health system in Australia. The inclusion of rhNELL-1 in the NB1 device is expected to enhance bone formation. CEO Jeffrey Frelick expressed optimism about moving into human testing with Avania's support.
Bone Biologics Corporation (NASDAQ: BBLG) has announced advancements in their lead product, NB1, utilizing NELL-1 for spinal fusion treatments. The global market for bone graft substitutes is estimated at $3 billion annually, with additional opportunities for osteoporosis and trauma treatments worth $11 billion and $8 billion, respectively. A successful preclinical study on sheep supports NB1's efficacy. The company has secured $5.1 million in recent financing to commence a 30-patient pilot study in Australia in 2023.
On October 13, 2022, WallachBeth Capital LLC announced the closure of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), generating total gross proceeds of $5,100,000. The offering included 3,777,778 units at $1.35 per unit, each comprised of one share of common stock and three different Series warrants. The warrants have various exercise prices and expiration timelines, with some allowing cashless exercises. Underwriters were granted a 45-day option to purchase additional securities. The offering was made under an SEC registration statement that became effective on October 6, 2022.
Bone Biologics Corporation (NASDAQ: BBLG) has completed its underwritten public offering, raising $5,100,000 in gross proceeds. The offering consisted of 3,777,778 units priced at $1.35 each. Each unit includes one share of common stock and several warrants with varying exercise prices. The company intends to utilize the net proceeds for clinical trials, patent maintenance, research organization retention, and general corporate purposes. There is a 45-day option for underwriters to purchase additional shares or warrants.